Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586530 | 0.88 | HTR6 (0.55) | HTR6HTR1AHTR2ACYP2D6 | |
| SCHEMBL6589952 | 0.78 | HTR6 (0.49) | HTR6DRD2HTR2A | |
| SCHEMBL1136509 | 0.77 | HTR6 (1.00) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL6587948 | 0.74 | MET (0.46) | HTR6HTR2A | |
| SCHEMBL5200503 | 0.74 | HTR6 (0.73) | HTR6HTR1ADRD2HTR2A | |
| Ammonia Solution, Strong SCHEMBL6589958 | 0.72 | HTR6 (0.51) | HTR6 | |
| SCHEMBL5202253 | 0.72 | HTR6 (0.69) | HTR6HTR1ADRD2HTR2ACYP3A4 | |
| SCHEMBL4318310 | 0.71 | HTR6 (0.72) | HTR6HTR1ADRD2HTR2ACYP3A4 | |
| SCHEMBL5203279 | 0.71 | HTR6 (0.76) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL4309765 | 0.71 | HTR6 (0.70) | HTR6HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | SMITHKLINE BEECHAM PLC (GB) | 2004-12-02 | — | — | US | claimed |
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | SMITHKLINE BEECHAM PLC (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1414442-A1 | 3-ARYLSULFONYL-7-PIPERAZINYL- INDOLES, -BENZOFURANS AND -BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003013510-A1 | 3-ARYLSULFONYL-7-PIPERAZINYL- INDOLES, -BENZOFURANS AND -BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | HTR6, HTR7, HTR1A | HTR6 1/4885HTR1A 3/4885DRD2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.